Market Overview - On June 16, despite escalating tensions in the Middle East, the Hong Kong stock market showed resilience, with the Hang Seng Index rising 0.7% to close at 24,060 points[1] - The Hang Seng Tech Index increased by 1.2%, closing at 5,299 points, with a trading volume of HKD 229.2 billion, indicating relative market activity[1] - Net inflow from the Hong Kong Stock Connect was HKD 5.7 billion, reflecting continued interest in the market[1] Sector Performance - Technology stocks generally performed well, with Xiaomi (1810 HK) up 4.2% and Kuaishou (1024 HK) rising over 3%[1] - Real estate and Chinese brokerage stocks remained strong, with major banks like China Construction Bank (939 HK) and Agricultural Bank of China (1288 HK) reaching historical highs[1] - Defensive sectors saw a decline, particularly gold stocks, with Lingbao Gold (3330 HK) dropping 12%[1] Economic Insights - In May, China's economy showed signs of moderate recovery, with retail sales improving month-on-month but continuing to exhibit internal structural disparities[2] - The International Institute of Finance (IIF) reported a USD 5.2 billion inflow into the Chinese market from the beginning of the year until May, although foreign investment in Chinese stocks remains significantly underweight[2] - The Hang Seng Index's valuation is at the 60th percentile of the past seven years, with the AH premium near a three-year low, suggesting limited short-term catalysts for the market[2] Real Estate Trends - New home sales in 30 major cities reached 1.74 million square meters, a year-on-year decline of 3.0%, but an improvement from the previous week's 18.1% drop[3] - The decline in new construction and completion areas was less severe than in April, with decreases of 18.7% and 19.1%, respectively[3] Automotive Sector Developments - Xiaomi announced the upcoming launch of its new car model YU7, alongside several other significant product releases, boosting its stock price by 4.2%[4] Pharmaceutical Sector Updates - CSPC Pharmaceutical (1093 HK) is set to receive USD 1.1 billion in upfront payments from AstraZeneca for multiple drug candidates, with potential milestone payments reaching USD 16.2 billion[5] Investment Strategy - The report suggests a focus on high-dividend defensive sectors like energy and telecommunications, while also considering undervalued tech stocks with growth potential as market conditions stabilize[2][10]

Market Overview - The Hang Seng Index rose only 0.4% last week, closing at 23,892 points, influenced by escalating geopolitical tensions in the Middle East[1] - The Hang Seng Tech Index fell 0.9% to 5,239 points, while the Hang Seng China Enterprises Index increased by 1.7%, marking its fifth consecutive week of gains[1] - The healthcare sector index surged by 8.8%, and the materials index rose by 7.0%, driven by gold and non-ferrous metal stocks[1] Economic Indicators - May's core CPI showed mild growth, while PPI's decline widened, indicating uneven economic recovery[1] - Export data was supported by "grabbing exports" and "grabbing transshipments," but imports fell more than expected, reflecting weak domestic demand[1] - M1's year-on-year growth accelerated to 2.3%, the highest since January 2024, indicating improved business activity[1] Sector Performance - The consumer sector saw a continued interest in new consumption stocks, with companies like Lao Pu Gold and Mx Group rising between 2% and 11% last week[3] - The automotive sector experienced a decline, with traditional car manufacturers averaging a drop of 1.3% and new energy vehicle companies down 3.8%[3] - The healthcare index rose 8.5%, with major players like China Biopharmaceuticals announcing significant overseas licensing deals[3] Investment Recommendations - The valuation of the Hang Seng Index has recovered to around the 60th percentile over the past seven years, suggesting potential for further upward movement in the second half of the year[2] - Short-term outlook indicates a lack of catalysts for the market, with expectations of high-level consolidation and sector rotation opportunities[2] - Focus on defensive dividend sectors (energy, telecommunications) and relatively undervalued, high-growth potential stocks in the Hang Seng Tech Index[2] Company Insights - Weisheng Holdings is projected to see net profits rise from RMB 710 million in FY24 to RMB 1.4 billion in FY27, with a CAGR of 25.7%[5] - The company has been rated "Buy" with a target price of HKD 9.20, reflecting a 23.8% upside potential[5] - The pharmaceutical sector is highlighted for its strong overseas licensing potential, with companies like Hansoh Pharmaceutical and China Biopharmaceuticals showing promising growth prospects[10][13]

Market Overview - On June 11, the Hang Seng Index rose by 204 points or 0.8%, closing at 24,366 points, while the Hang Seng Tech Index increased by 1.1% to 5,451 points[1] - The total market turnover reached over HKD 235.2 billion, with a net inflow of HKD 1.37 billion through the Hong Kong Stock Connect[1] - Key sectors leading the market included insurance, brokerage, gaming, oil, coal, non-ferrous metals, and engineering machinery, while biomedicine, food and beverage, and utilities lagged behind[1] Sector Performance - Major state-owned banks saw stock increases ranging from 1.1% to 2.5%[1] - Brokerage stocks benefited from merger rumors, with GF Securities (1776 HK) surging 6.2% and others like Huatai (6886 HK) and CITIC Securities (6066 HK) rising between 4.1% and 4.9%[1] - The gaming sector received a boost from new supportive measures, with Bilibili (9626 HK) climbing 9.9%[1] Economic Indicators - The automotive sector reported a wholesale volume of 2.686 million units in May, up 11.2% year-on-year and 3.7% month-on-month, with cumulative sales for the first five months increasing by 10.9%[3] - New energy vehicle sales surged by 44% year-on-year, achieving a penetration rate of 44%[3] - The global healthcare sector saw a 33.8% month-on-month increase in financing, totaling USD 4.85 billion in May, indicating a recovery in investment[3] Real Estate Insights - New home sales in 30 major cities fell to 1.42 million square meters, down 18.1% year-on-year and 33.3% month-on-month, indicating a significant decline in the real estate market[5] - The inventory-to-sales ratio for major cities rose to 85.4, compared to 83.6 last year, reflecting a slower inventory turnover[7] - Land transaction volumes dropped by 48.9% year-on-year, with a significant decline in the number of transactions[8] Strategic Recommendations - The current market strategy suggests waiting for fund rotation rather than chasing high-flying stocks, as the market lacks a clear leading sector[2] - Investors are advised to focus on undervalued sectors with high growth potential, particularly in the Hang Seng Tech Index, while maintaining a defensive stance in dividend-paying sectors[13]

Market Overview - On June 10, the Hang Seng Index experienced a slight decline of 19 points or 0.1%, closing at 24,162 points[1] - The Hang Seng Tech Index fell by 0.8%, ending at 5,392 points[1] - Total market turnover reached HKD 250.3 billion, with the top two ETFs, the Tracker Fund and the Hang Seng China Enterprises ETF, recording turnover of HKD 16.5 billion and HKD 14.0 billion respectively[1] - Net inflow through the Stock Connect was HKD 7.59 billion[1] Sector Performance - Sub-sectors such as banking, insurance, power, biomedicine, materials, and transportation showed positive performance[1] - Agricultural Bank, China Construction Bank, and Industrial and Commercial Bank reached new highs since their listings[1] - Biomedicine stocks like Lepu Biopharma, CanSino Biologics, and 3SBio saw increases ranging from 9.8% to 15.5%[1] Valuation Insights - The current AH premium index has dropped to 130.5, indicating a low level within the past three years[2] - After accounting for a 20% dividend tax on H-shares, the adjusted AH premium index is approximately 125, suggesting limited upside for H-shares[2] - The Hang Seng Index's risk premium is nearing two standard deviations below its rolling two-year average, indicating insufficient market risk compensation[2] Economic Context - The economic fundamentals remain in a weak recovery phase, with ongoing downward pressure on prices and unstable corporate profit recovery[2] - If the Hong Kong dollar approaches the weak side of the peg, the Monetary Authority may withdraw liquidity, potentially raising funding costs[2] Real Estate Market Trends - New home transaction volume in 30 major cities fell to 1.42 million square meters, a year-on-year decline of 18.1%[5] - The inventory-to-sales ratio for major cities increased to 85.4, up from 83.6 a year ago[7] - Land transaction volume in 100 major cities dropped by 48.9% year-on-year, indicating a significant contraction in the real estate market[8] Investment Recommendations - Focus on state-owned developers for stability in the real estate sector, given the underperformance of Hong Kong-listed property stocks[11] - Monitor high-growth potential sectors such as consumer electronics and AI, which may benefit from reduced external risks[13]

Investment Rating - The report assigns a rating of "Buy" to Hansoh Pharmaceutical (3692 HK) with a target price of HKD 29.30 [6][8]. Core Insights - Hansoh Pharmaceutical has successfully entered into an overseas licensing agreement with Regeneron, which includes an upfront payment of USD 80 million and potential milestone payments of up to USD 1.93 billion, along with royalties on sales [6][8]. - The report highlights the strong performance of the new consumption stocks, particularly the significant price increases of companies like Blok (325 HK) and the mixed performance of Gu Ming (1364 HK) and Mixue Group (2097 HK) after being included in the Hong Kong Stock Connect [3][4]. - The healthcare sector, particularly the biotech companies, has shown robust growth, with the Hang Seng Healthcare Index rising by 4.8%, outperforming the Hang Seng Index [4]. Summary by Sections Macro Dynamics - The new housing transaction volume in major cities has seen a year-on-year decline of 18.1%, indicating a weakening real estate market [2]. Industry Dynamics - The new consumption sector has been positively impacted by the inclusion in the Hong Kong Stock Connect, with notable stock price increases [3]. - The AI sector is gaining traction, with Fourth Paradigm (682 HK) seeing a 9.7% increase due to positive quarterly results and new AI solutions for the healthcare industry [3]. Healthcare Sector - The healthcare index has outperformed the broader market, with significant gains from companies like Innovent Biologics (1801 HK) and others, driven by new drug approvals and clinical trial successes [4]. - The report emphasizes the potential of Hansoh Pharmaceutical's new drug HS-20094, which has completed several Phase II clinical trials and is recognized for its quality by Regeneron [6][8]. Energy Sector - The report suggests a cautious approach towards the new energy sector, with mixed performances observed in solar stocks and a positive outlook for coal-fired power generation due to low coal prices [10][11]. - The nuclear energy sector is expected to benefit from increased demand for uranium, driven by U.S. initiatives to boost domestic nuclear energy production [13][15].

市场憧憬中美元首通电，港股大盘全周先跌后升，恒生指数全周上升 2.2%，收报 23,792 点。恒生科指全周上升 2.2%，收 报 5,286 点。恒指公司上周五季检生效，使大市成交金额增加至 2,356 亿港元，但全周日均成交也按周下跌 7.6%至 2,039 亿港元，显示大多投资者仍在观望中。港股通全周净流入 149 亿港元，风格继续偏好高分红。板块上，材料及医疗保健行 业分类指数上分别升大升 5.6%及 4.1%，前者受到黄金及铜有色股份带动，后者则受惠于市场对中国创新药 BD 交易的预 期。全球市场风险偏好上升有助于港股表现，但当前估值已大幅修复，AH 溢价指数偏低，整体大盘以偏震荡为主。由于 部分焦点板块升幅已较大，较易有获利了结的倾向，预计未来一周港股难有明确主线，更多以板块轮动为主。 中美元首上周通话，双方同意团队继续落实好日内瓦共识，尽快举行新一轮会谈。我们认为消息有助于纾缓中美双边紧 张气氛，减少不确定性，促进港股情绪进一步修复。不过，中美双方在关税税率、高端芯片的进口、市场改革、产业补 贴、芬太尼等多方面仍存在较多分歧，预计中美能够达成共识的进度较缓慢且反复。 上周个别年内升幅凌厉的"新消 ...

Market Overview - On June 5, the market sentiment improved due to expectations of a call between the US and Chinese leaders, leading to a rise in the Hang Seng Index by 253 points or 1.1%, closing at 23,906 points, the highest since March 20 this year [1] - The Hang Seng Tech Index increased by 1.9%, closing at 5,319 points, with total market turnover slightly increasing to HKD 222 billion, while net inflow from Hong Kong Stock Connect decreased to HKD 740 million [1] - Despite the positive market sentiment, trading volume did not significantly increase, indicating that many funds remain on the sidelines [1] Macro Dynamics - The US services sector contracted again, with the ISM Services PMI dropping to 49.9% in May, primarily due to a decline in new orders, which fell by 5.9 percentage points to 46.4%, the lowest since December 2022 [2] - The employment index in the services sector rose to 50.7%, indicating that companies are still hiring [2] - The divergence between ISM and Markit Services PMI suggests that international companies are more affected by tariff uncertainties, contributing to the slowdown in the US economy [2] Industry Dynamics - New consumption sector leaders experienced a pullback, with Lao Pu Gold (6181 HK) dropping 9.0% after reaching over HKD 1,000, despite positive market sentiment towards its new product series [3] - The Hang Seng Healthcare Index fell by 1.3%, with major companies showing little volatility [3] - In the energy sector, the Hong Kong utility sector generally rose, with Cheung Kong Infrastructure (1038 HK) increasing by 2.1% amid speculation about potential acquisitions [4] Energy Sector Insights - The coal price remains weak, with the Qinhuangdao 5500 kcal thermal coal spot price at RMB 613 per ton, down 30.3% year-on-year [6] - The upcoming summer season is expected to boost demand for thermal power, making it a favorable time for thermal power stocks [6] - The Chinese government is promoting green electricity development, which may enhance the consumption of renewable energy [7] Company-Specific Insights - Huaneng International (902 HK) reported an 8.2% year-on-year increase in net profit for Q1 2025, benefiting from lower fuel costs and increased summer electricity demand [10] - China General Nuclear Power Corporation (1164 HK) signed a framework agreement for uranium sales, positioning itself to benefit from rising uranium prices due to increased demand from US nuclear energy initiatives [10] - New Hope Energy (2688 HK) is undergoing privatization, with its current price showing a 24.3% discount compared to the privatization offer, making it an attractive investment opportunity [10]

Market Overview - The Hong Kong stock market continued its rebound with the Hang Seng Index rising by 0.6% to close at 23,654, while the Hang Seng Tech Index also increased by 0.6% to 5,219. The trading volume reached HKD 212.6 billion, indicating active trading, although net inflows from the Stock Connect decreased by about 10% to HKD 3.5 billion [1] - The market showed a "stronger gets stronger" trend, with funds continuing to favor high-certainty stocks. New consumption leaders like Pop Mart (9992 HK) and Mao Geping (1318 HK) reached new highs, reflecting market premium recognition for scarce consumer brands [1] Macro Dynamics - In the U.S., job vacancies rose to 7.391 million in April, an increase of 191,000 from March, indicating resilience in the labor market. The ratio of job openings to job seekers remained at 1.03, consistent with 2019 levels [2] - Despite a rise in layoffs to 1.79 million, the layoff rate remains relatively low, suggesting that companies are hesitant to reduce staff amid a moderately slowing economy [2] Industry Dynamics Automotive Sector - The Chinese government is promoting the "2025 New Energy Vehicles Going to the Countryside" initiative, with 124 models included in the directory, including vehicles from BYD and Geely. The automotive sector in Hong Kong showed stable performance, with most stocks fluctuating between -1% and +2% [3] Consumer Sector - The new consumption and IP concept sectors continue to attract capital. Companies like Blucor (325 HK) have entered the Mexican market, showcasing their product matrix at exhibitions. Blucor and Pop Mart saw respective increases of 17% and 14% over the past five trading days [3] Healthcare Sector - The Hang Seng Healthcare Index rose by 3.2%, driven by recent licensing agreements between domestic pharmaceutical companies and global firms, boosting confidence in the export of innovative drugs. Companies like Innovent Biologics (1801 HK) reported promising clinical data at the ASCO conference, leading to a 14.1% surge in their stock price [4] Energy Sector - The energy sector, particularly nuclear and renewable energy stocks, saw significant gains. China General Nuclear Power (1164 HK) rose by 28.3% after signing a uranium sales framework agreement, benefiting from rising uranium prices due to increased demand from U.S. nuclear energy initiatives [5][9] Company-Specific Insights Huaneng International (902 HK) - The company reported an 8.2% year-on-year increase in net profit for Q1 2025, benefiting from lower fuel costs and increased electricity demand during the summer [11] China General Nuclear Power (1164 HK) - The company is expected to benefit from a new uranium sales agreement, with a pricing mechanism favoring current market prices, enhancing its position amid rising uranium demand [11] Stone Pharmaceutical (1093 HK) - The company experienced a 21.9% decline in total revenue for Q1 2025, primarily due to a slowdown in its core product sales. However, it anticipates a gradual recovery in sales starting from Q2 2025, supported by new licensing agreements and increased sales of oncology drugs [13][14][15]

Investment Rating - The report assigns a "Neutral" rating to the company with a target price raised to HKD 7.40 from HKD 6.30 [4][6]. Core Insights - The company's total revenue for Q1 2025 decreased by 21.9% year-on-year to RMB 7.01 billion, while net profit attributable to shareholders fell by 8.4% to RMB 1.48 billion. Excluding RMB 718 million in licensing fee income, product sales revenue was approximately 4.6% lower than expected, primarily due to a slowdown in the sales of established drugs [1][4]. - The report anticipates a gradual recovery in product sales revenue starting from Q2 2025, as the impact of centralized procurement for certain oncology drugs has already been reflected, and sales are expected to increase after the inclusion of new drugs in the medical insurance list by the end of 2024 [2][4]. - The company is expected to achieve multiple significant overseas licensing agreements, with Q1 licensing fee income of RMB 718 million primarily from agreements with BeiGene and AstraZeneca. These agreements involve upfront payments totaling USD 250 million (approximately RMB 1.8 billion) and potential milestone payments of up to USD 3.56 billion (approximately RMB 25.6 billion) [3][4]. Financial Summary - The company's projected total revenue for 2025 is RMB 29.89 billion, reflecting a 3.0% growth rate, while net profit is expected to be RMB 4.77 billion, a 10.2% increase. The earnings per share (EPS) is projected at RMB 0.41, with a price-to-earnings (P/E) ratio of 17.4 [5][13]. - The financial data indicates a decline in established drug sales, with revenue from the core product Enbrel decreasing by 29.5% year-on-year, and oncology drug sales dropping by 65.7% due to centralized procurement impacts [1][5]. - The report includes a detailed financial forecast, showing total revenue growth rates of 1.7% in 2023, a decline of 7.8% in 2024, and subsequent growth rates of 3.0%, 12.8%, and 12.6% for 2025, 2026, and 2027 respectively [5][13].

Market Overview - The Hong Kong stock market rebounded on June 3, with the Hang Seng Index rising by 1.5% to close at 23,512 and the Hang Seng Tech Index increasing by 1.1% to 5,189, indicating a significant recovery in market sentiment [1] - The trading volume reached HKD 203.7 billion, showing a notable increase compared to previous days, although the net inflow from the Stock Connect was only HKD 3.9 billion [1] - Major financial stocks, including CITIC Bank, Industrial and Commercial Bank of China, and Agricultural Bank of China, hit historical highs, reflecting continued investment in high-dividend defensive assets [1] Industry Dynamics - The automotive sector saw a rebound, with Xiaomi's automotive business losses decreasing and expectations for profitability in Q3 or Q4 of this year, driven by the upcoming launch of the YU7 model [3] - The healthcare sector also performed well, with the Hang Seng Healthcare Index rising by 2.5%. Notable gains were seen in companies reporting positive clinical data at the American Society of Clinical Oncology (ASCO) [3] - The renewable energy and utilities sectors experienced widespread gains, with Goldwind Technology rising by 13.3% due to share buyback plans and the establishment of an AI-related subsidiary [4] Company-Specific Insights - The report on CSPC Pharmaceutical Group indicated a 21.9% year-on-year decline in total revenue for Q1 2025, amounting to RMB 7.01 billion, primarily due to a slowdown in the sales of its core products [5] - The company expects a gradual recovery in product sales starting from Q2 2025, as the impact of centralized procurement has already been reflected in Q1 results [6] - CSPC has secured multiple overseas licensing agreements, with expected upfront payments totaling approximately RMB 1 billion and potential milestone payments exceeding RMB 25.6 billion, indicating strong future revenue prospects [7][8] Real Estate Sector Analysis - The report on the Chinese real estate market highlighted a 12.0% year-on-year decline in new home transaction volume across 30 major cities, with first-tier cities showing resilience [9] - First-tier cities like Shanghai and Shenzhen reported increases in cumulative transaction volumes, with Shanghai up by 9.5% and Shenzhen by 45.8% year-on-year [10] - The land transaction volume in 100 major cities fell by 46.9% year-on-year, indicating ongoing challenges in the real estate sector [12]